EMJ Oncology 8 [Supplement 2] . 2020

In this issue

Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy (ET) are considered the standard-of-care treatment for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative (-) advanced breast cancer (ABC). The latest developments in the treatment of this cancer were covered during the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, from 28th–29th September 2019.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.